Prone Positioning of Non-intubated Patients with COVID-19 - A Systematic Review and Meta-analysis

Mallikarjuna Reddy PONNAPA REDDY (malli_ponnu@yahoo.co.in)  
Calvary Public Hospital  
https://orcid.org/0000-0002-4736-2901

Ashwin SUBRAMANIAM  
Peninsula Health

Zheng Jie LIM  
Ballarat Health Services

Alexandr ZUBAREV  
Peninsula Health

Afsana AFROZ  
Monash University School of Public Health and Preventive Medicine

Baki BILLAH  
Monash University School of Public Health and Preventive Medicine

Gabriel BLECHER  
Monash health emergency department

Ravindranath TIRUVOIPATI  
Peninsula Health

Kollengode RAMANATHAN  
National University Hospital

Suei Nee WONG  
National University of Singapore

Daniel BRODIE  
New York Presbyterian Hospital

Eddy FAN  
University of Toronto

Kiran SHEKAR  
The Prince Charles Hospital

Research

Keywords: COVID-19, SARS-CoV-2, hypoxaemic respiratory failure, Awake proning, Prone positioning, Oxygenation, Endotracheal intubation

DOI: https://doi.org/10.21203/rs.3.rs-99735/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Purpose:** Several studies have reported adopting prone positioning (PP) in non-intubated patients with COVID-19-related hypoxaemic respiratory failure. This systematic review and meta-analysis evaluated the impact of PP on oxygenation and clinical outcomes.

**Methods:** We searched PubMed, Embase and the COVID-19 living systematic review from December 1, 2019 to July 23, 2020. We included studies that reported using PP in hypoxaemic, non-intubated adult patients with COVID-19. Primary outcome measured was the weighted mean difference (MD) in oxygenation parameters (PaO$_2$/FiO$_2$, PaO$_2$ or SpO$_2$) pre and post-PP.

**Results:** Fifteen single arm observational studies reporting PP in 449 patients were included. Substantial heterogeneity was noted in terms of, location within hospital where PP was instituted, respiratory supports during PP, and frequency and duration of PP. Significant improvement in oxygenation was reported post-PP: PaO$_2$/FiO$_2$ (MD 37.6, 95% CI 18.8-56.5); PaO$_2$ (MD 30.4 mmHg, 95% CI 10.9 to 49.9); and SpO$_2$ (MD 5.8%, 95% CI 3.7 to 7.9). Patients with a pre-PP PaO$_2$/FiO$_2$ ≤150 experienced greater oxygenation improvements compared with those with a pre-PP PaO$_2$/FiO$_2$ >150 (MD 40.5, 95% CI -3.5 to 84.6) vs. 37, 95% CI 17.1 to 56.9). Respiratory rate decreased post-PP (MD -2.9, 95% CI -5.4 to -0.4). Overall intubation and mortality rates were 21% (90/426) and 26% (101/390) respectively. There were no major adverse events reported.

**Conclusions:** Despite the significant variability in frequency and duration of PP and respiratory supports applied, PP was associated with improvements in oxygenation parameters without any reported serious adverse events. The results are limited by lack of control arm and adjustment for confounders. Clinical trials are required to determine the effect of awake PP on patient-centred outcomes.

**Systematic review registration:** Registration/protocol in PROSPERO (CRD42020194080).

**Take-home Message**

Prone positioning in non-intubated severe COVID 19 patients demonstrated improvements in their oxygenation. However, significant heterogeneity in duration, frequency of prone positioning and in the other respiratory supports provided limit further interpretation. Whether this improvement in oxygenation results in meaningful patient-centred outcomes needs testing in clinical trials.

**Introduction**

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mainly affects the respiratory system and can lead to acute hypoxaemic respiratory failure. 0.9–32% of these patients require admission to intensive care units (ICU) for advanced respiratory support [1–4]. A surge in critically ill patients with respiratory failure has overwhelmed ICU capacity in many healthcare systems across the world. Studies published during the early phase of the pandemic have showed poor outcomes in invasively ventilated COVID-19 patients. Given a guarded prognosis and significant resource constraints less-invasive, innovative approaches such as prone positioning (PP) of non-intubated patients with hypoxaemic respiratory failure was considered. They were initiated in emergency departments (ED), hospital wards, or in ICUs as an adjunct to conventional oxygen therapies, high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV) [5, 6].

The potential efficacy of PP with hypoxaemic respiratory failure is yet to be meaningfully tested in well-designed clinical trials. Limited data suggests that PP in non-intubated patients is feasible and is associated with an improvement in oxygenation in patients with respiratory failure [7]. There have been case reports and cohort studies that report the use of PP of non-intubated patients with COVID-19 during the pandemic [2, 8–10]. Conceptually, awake PP is relatively less time and resource consuming as compared to PP in intubated patients. Theoretically, they may decrease the risks of adverse events seen in intubated prone patients.

Deteriorating oxygenation despite optimal less-invasive respiratory support [11] is one of the common triggers for invasive mechanical ventilation. PP improves oxygenation by increasing ventilation–perfusion matching by the recruitment of the larger number of alveolar units located in dorsal areas of the lungs [12, 13]. Furthermore, in patients with COVID-19, PP may also enable gravity assisted diversion of pulmonary blood flows to dorsal regions in the setting of pulmonary vascular dysregulation and loss of hypoxic pulmonary vasoconstriction response in selected patients [14]. Thus, the success of PP largely hinges on its ability to reliably and predictably improve oxygenation, which may then subsequently improve the respiratory drive, thereby decreasing the risk of self-inflicted lung injury or respiratory fatigue.

Little is known about the magnitude of the effect of PP on oxygenation and its ability to improve patient-centred outcomes in non-intubated COVID-19 patients. Therefore, we performed this systematic review and meta-analysis to evaluate the effect of PP on oxygenation parameters. Secondary analysis included rates of endotracheal intubation and in-hospital mortality.

**Methods**

The protocol for this systematic review and meta-analysis was registered with PROSPERO (CRD42020194080). The study was conducted in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement [15].

**Eligibility criteria**

Studies on laboratory-confirmed SARS-CoV-2 hypoxaemic adult patients (≥ 18 years of age) requiring supplemental oxygen who received PP were included. Studies were excluded if (a) they were systematic reviews (b) they did not report on oxygenation parameters (either PaO$_2$, SpO$_2$ or PaO$_2$/FiO$_2$) (c) case reports...
or case series with fewer than 5 patients (to decrease reporting bias). The corresponding authors of a study were contacted for missing information required for the analysis.

**Search strategy, Information Sources and Study Selection**

Two authors (MR and AZ) independently searched on PubMed, Embase, Cochrane, Scopus and the COVID-19 living systematic review from December 1st, 2019 to July 23rd, 2020. COVID-19 living systematic review has a daily-updated list of pre-print and published articles relating to COVID-19 obtained from PubMed, EMBASE, medRxiv and bioRxiv [16]. The living systematic review was previously used during the Zika virus epidemic [17] and recently has been validated against an Ovid search relating to COVID-19 [18]. Search terms were “Prone”, “Prone Position*” or “Proning” along with “COVID-19”-related terms were used within the title and abstract columns of the systematic review list. Our search was further supported by medical librarian search that was carried out independently (SW). A detailed search terms and tools are summarised in Additional Table 1. No language restrictions were applied.
<table>
<thead>
<tr>
<th>Author, reference</th>
<th>n*</th>
<th>Settings</th>
<th>Patient location of PP</th>
<th>Supplemental oxygen and non-invasive respiratory support</th>
<th>Number of episodes, And duration of PP (hours)</th>
<th>Mean duration of PP when respiratory parameters were assessed (minutes)</th>
<th>Respiratory physiology parameters reported pre- and post PP</th>
<th>Other outcome parameters reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caputo et al [2]</td>
<td>50</td>
<td>Single Centre, NY, USA.</td>
<td>ED</td>
<td>NRB and NC</td>
<td>1, (NR)</td>
<td>5</td>
<td>D</td>
<td>NR</td>
</tr>
<tr>
<td>Coppo et al [26]</td>
<td>46</td>
<td>Single Centre, Monza, Italy</td>
<td>ED, Respiratory HDU</td>
<td>NIV, VM and NRB</td>
<td>1–3, (3.5 hrs)</td>
<td>10</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Damarla et al [27]</td>
<td>10</td>
<td>Single Centre, Baltimore, USA</td>
<td>ICU</td>
<td>HFNC and NC</td>
<td>Multiple (2 hrs)</td>
<td>60</td>
<td>D</td>
<td>+</td>
</tr>
<tr>
<td>Despres et al [10]</td>
<td>6</td>
<td>Single Centre, Besancon, France</td>
<td>ICU</td>
<td>HFNC or VM</td>
<td>Multiple (1–7 hrs)</td>
<td>180</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>Dong et al [37]</td>
<td>25</td>
<td>Single Centre, Wuhan, China</td>
<td>ICU</td>
<td>HFNC, VM, NC and NIV</td>
<td>Daily (4.9)</td>
<td>294</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Elharrar et al [36]</td>
<td>24</td>
<td>Single Centre, France</td>
<td>NR</td>
<td>NC and HFNC</td>
<td>&lt; 1 h, 1-3hrs, &gt;3hrs</td>
<td>90</td>
<td>D</td>
<td>+</td>
</tr>
<tr>
<td>Golestani-Eraghi et al [35]</td>
<td>10</td>
<td>Single Centre, Teheran, Iran</td>
<td>ICU</td>
<td>NIV</td>
<td>NR/multiple (14 hr)</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>Lawton et al [28]</td>
<td>165</td>
<td>Single Centre, Bradford, UK</td>
<td>Ward, ED</td>
<td>NIV</td>
<td>2 times/day</td>
<td>30</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Moghadam et al [34]</td>
<td>10</td>
<td>Single Centre, Qom, Iran</td>
<td>ICU</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>+</td>
</tr>
<tr>
<td>Retucci et al [33]</td>
<td>26</td>
<td>Single Centre, Milan, Italy</td>
<td>Respiratory HDU</td>
<td>NIV</td>
<td>29 (1 hr)</td>
<td>60</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sartini et al [32]</td>
<td>15</td>
<td>Single Centre, Milan, Italy</td>
<td>ICU/medical ward</td>
<td>NIV</td>
<td>1–3 (1-6hrs)</td>
<td>60</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thompson et al [31]</td>
<td>29</td>
<td>Single Centre, NY, USA.</td>
<td>HDU</td>
<td>NRB and NC</td>
<td>1 hr</td>
<td>60</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>Tu et al [30]</td>
<td>9</td>
<td>Single Centre, Shanghai, China</td>
<td>ICU</td>
<td>HFNC and NIV</td>
<td>3–8 (1–4 hrs)</td>
<td>120</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>Xu et al [29]</td>
<td>10</td>
<td>Single Centre, Anhui, China.</td>
<td>ICU</td>
<td>HFNC</td>
<td>3 (16 hrs)</td>
<td>300</td>
<td>+</td>
<td>NR</td>
</tr>
</tbody>
</table>
Quality Assessment and risk of bias in individual studies

The Newcastle-Ottawa Scale (NOS) [19] was used to assess the quality of cohort studies while Joanna Briggs Institute Critical Appraisal Checklist [20] was used to evaluate case series. Using relevant appraisal tools, each study was objectively evaluated by two reviewers independently (MR and ZL). Any discrepancies in the approval scores were resolved and reviewed by an additional reviewer (AS) (Additional Table 2).

Study Outcomes

The primary outcome was the change in oxygenation (i.e., PaO2/FiO2 ratio, PaO2, and SpO2) following PP. Different variables, such as the saturation of peripheral oxygen (SpO2), the partial pressure of arterial oxygen (PaO2), and the ratio of PaO2 to the fraction of inspired oxygen (PaO2/FiO2), have been used in the reported studies. We derived the PaO2 from SpO2 and vice versa if they were not reported in studies using the accepted conversion formulae for consistency to analyse the data (Additional Table 3) [21]. For small number of studies an estimation formula was used to convert median to mean values (Additional Table 4) [22]. Median was derived for PaO2 in 3 studies, for SpO2 in 5 studies and for PaO2/FiO2 in 2 studies. Sensitivity analyses for physiological parameters were performed by restricting to studies with sample sizes ≥ 20.

The secondary outcomes included endotracheal intubation rate and mortality. Major adverse events were defined as cardiac arrest, clinically significant haemodynamic instability or accidental dislodgment of intravenous line following PP. Post hoc subgroup analyses were performed to compare: (1) the primary outcome between patients with pre-PP PaO2/FiO2 > 150 and PaO2/FiO2 ≤ 150; and (2) the primary and secondary outcomes in patients depending on the location within hospital where PP was initiated (within ICU vs. outside ICU). We also performed an exploratory post hoc analysis on the changes in patients’ respiratory rate (RR) after PP.

Data Analysis

Statistical analyses were performed using the statistical software package Stata-Version 16 (Statacorp, USA). Mean (standard deviation [SD]) or median (interquartile range [IQR]) were used for numerical data and proportion for categorical data. We report weighted mean difference (MD) with 95% confidence intervals (95%-CI) for physiological parameters and event rates using a random effects model to account for both within-study and between-study variances. [23] Results were presented in Forest plots. Heterogeneity was tested using the χ² test on Cochran's Q statistic, which was calculated using H and I² indices. The I² index estimates the percentage of total variation across studies based on true between-study differences rather than on chance. Conventionally, [I² values of 0–25% indicate low heterogeneity, 26–75% indicate moderate heterogeneity, and 76–100% indicate substantial heterogeneity [24]. A post-hoc subgroup analysis using different sample sizes was carried out to identify the possible causes of substantial heterogeneity.[24] Due to concerns of the limited available data we could not pre-specify the exact variables for subgroup analysis. Following data collection, we carried out two subgroup analyses on oxygenation and clinical outcomes: ICU vs. non-ICU (emergency department [ED], respiratory wards, high dependency units [HDU]) and baseline PaO2/FiO2 ratio (PaO2/FiO2 ≤ 150 and > 150). Symmetry of the funnel plots was evaluated, and the Egger's regression test was used to examine for publication bias [25]. A p-value < 0.05 was considered significant.

Results

From 248 studies we identified 15 eligible studies [2, 9, 10, 26–37] and a total of 449 patients were included in the final analysis (Fig. 1) The 15 included studies are summarised in Table 1. The reports originated from 6 countries (China, France, Iran, Italy, USA and UK). 287 patients were men (63.9%) with a mean age (SD) of 56 (7) years. The patients received PP for a variable duration (median 180 minutes, IQR 37.5-264.75) and this procedure was repeated 1–13 times/day during their hospital stay or until intubation, if it occurred. Data on oxygen therapy provided during PP was reported in 350 patients. 68.9% (241/350) received NIV, 4.9% (17/350) on HFNC, 13.7% (48/350) received oxygen via face mask, 12.6% (44/350) via low-flow nasal cannula. Among the 277 patients for whom FiO2 was reported, 175 (63.2%) of them received FiO2 < 50%, 46 (16.6%) were on FiO2 between 50–70% and 56 (20.2%) of them received FiO2 ≥ 70%.
In the 420 patients for whom data on the location of provision of PP was available, 111 patients (26.4%) received PP in ICU and 309 (73.6%) outside ICU (respiratory wards, high dependency units or emergency departments).

**Primary outcome:**

The improvements in physiological parameters (PaO₂/FiO₂, PaO₂, SpO₂) before and after PP are presented graphically in Fig. 2.

**PaO₂/FiO₂ post-PP**

The ratio was reported in 11 studies [2, 9, 10, 27–30, 32, 33, 35, 37]. The PaO₂/FiO₂ improved post PP (MD 37.6, 95%-CI 18.8, 56.5; p = 0.001) (Fig. 3). Heterogeneity persisted despite analysing studies with a sample size of more than 20 patients (4 studies [2, 9, 28, 33], I² = 97.1% p = 0.001) (Additional Fig. 1). However, the Egger's regression test ruled out publication bias (p = 0.38).

**PaO₂ post-PP**

PaO₂ was reported or derived from SpO₂ in 13 studies [2, 9, 26–36] (Fig. 3). An improvement in PaO₂ was demonstrated following PP (MD 30.4, 95%-CI 10.9, 49.9). The heterogeneity was high (I² = 99.8%) (Additional Fig. 2). Egger's regression test (p < 0.001) suggests, presence of a publication bias. The heterogeneity continued to be high when only studies with more than 20 patients [2, 9, 26, 28, 31, 33, 36] (I² = 99.9%; p = 0.001) were analysed.

**SpO₂ post-PP**

SpO₂ was reported in 12 studies [2, 9, 27–36]. Improvement in SpO₂ (MD 5.8, 95%-CI 3.7, 7.9; p = 0.001) was seen across all studies where SpO₂ was obtained (Fig. 3). However, there was high heterogeneity (I² = 94.4%) and Egger's regression test ruled out publication bias (p = 0.82). The heterogeneity continued to be high when only studies with more than 20 patients (6 studies [2, 9, 28, 31, 33, 36] I² = 99.9%; p = 0.001) (Additional Fig. 3).

Funnel plots and Egger's Regression test for PaO₂/FiO₂, PaO₂ and SpO₂ are presented in Additional Fig. 4.

**Secondary Outcomes:**

Intubation after a trial of PP was reported in 14 studies [2, 10, 26–37]. A total of 90 patients out of 426 (21.1%) were intubated following a trial of PP. The studies demonstrated moderate heterogeneity (I² = 74.3%). The Forest plot and Funnel plot for intubation is presented in Fig. 4. However, there was no publication bias (Egger's regression test p = 0.52).

Mortality in patients who underwent awake PP was reported in 13 studies [9, 10, 26–29, 31–37]. Overall, 101 patients out of 390 (25.9%) died. The studies demonstrated high heterogeneity (I² = 83.6%), however, there was minimal publication bias (Egger's regression test p = 0.51). The Forest plot and Funnel plot for intubation is presented in Fig. 4.

Funnel plots and Egger's Regression test for intubation and mortality are illustrated in Additional Fig. 5.

There were no reported life-threatening or major adverse events following PP. Only reported minor events included pain in the back, sternum or scrotum; general discomfort, dyspnoea and coughing and confusion in a small number of patients [26, 36, 37].

Oxygenation outcomes were analysed based on the mean pre-PP PaO₂/FiO₂ ≤ 150 (5 studies [10, 28, 29, 33, 37]) or > 150 (6 studies [2, 9, 27, 30, 32, 35]). Patients with a Pre-PP PaO₂/FiO₂ ≤ 150 had statistically significant oxygenation improvements post-PP (MD = 37 [95%-CI 17.1–56.9] vs. MD = 40.5 [95%-CI 12.9–69.7]); however, the difference was statistically insignificant between ICU (MD = 23.8 [95%-CI 14.7–32.9]), whereas the improvement was insignificant in non-ICU group (MD = 49.4 [95%-CI 6.6–105.5]). The overall improvement in SpO₂ was 6.0% (95%-CI 3.8–8.2), however, the difference was statistically insignificant between ICU (MD = 5.82 95%-CI 2.46–9.16) and non-ICU (MD = 6.54 95%-CI 4.31–8.76) location for PP (p = 0.73). Of the 90 patients who were subsequently intubated, 64 patients (71.1%) received PP outside ICU (28.9% [26/90] in ICU vs. 71.1% [64/90]; p = 0.002). Mortality data were available in 12 studies [9, 10, 26–29, 31–34, 36, 37] where patients had PP either in ICU or outside ICU. A total of 23/255 patients died (12.6% [14/111] in ICU vs. 9.6%. [9/94] in Non-ICU areas; p = 0.49).

**Discussion**

This systematic review examined the effect of PP of non-intubated patients on oxygenation parameters in a heterogenous group of adult patients with COVID-19-related hypoxaemic respiratory failure. There was a significant improvement in oxygenation parameters (PaO₂/FiO₂, PaO₂ and SpO₂) and respiratory rate upon PP. An improvement in these parameters was consistent, although there was significant variability in both treatment dose and effect. However, due to the
inconsistency of reporting physiologic outcomes, it was unclear which of these parameters may provide the best clinical guidance in terms of both patient selection for PP and evaluation of treatment response. Other relevant data for example, relative changes in patients respiratory drive, dyspnoea scores and patient comfort were not consistently available. Given these limitations, the population that clearly stands to benefit from PP could not be clearly defined.

Although all patients demonstrated improved oxygenation, the patients with PaO₂/FiO₂ ratio of ≤ 150 demonstrated a greater improvement. The reasons may possibly be that patients with more severe hypoxaemia had a greater degree of pulmonary vascular dysregulation and ventilation: those with perfusion mismatch to start with and benefited more with PP. However, such an interpretation is speculative and not much inference can be drawn from these data as an improved oxygenation with PP depends on several factors such as timing, duration, underlying pathophysiology and other respiratory supports used. For example, the duration of and frequency of prone ventilation were quite variable with some studies reporting a combination of lateral positioning and PP. Such variability is a concern when it comes to feasibility and generalisability of PP outside of centres that have some experience in PP of awake patients.

In addition, there was significant heterogeneity in oxygen therapies provided prior to and during PP. For example, 69% of the patients were receiving NIV and 12.6% were receiving oxygen via nasal cannula. These two populations can be drastically different and may represent different stages of disease evolution. This is likely to have a significant bearing on adjunctive use of PP as essentially the outcomes depend on the success of combinations of these therapies. It should be noted that ARDS studies only tested PP in intubated patients enrolled patients with a PaO₂/FiO₂ ≤ 150 to bring in some homogeneity in an otherwise heterogeneous population of ARDS. In a recent network meta-analysis of trials of adult patients with acute hypoxaemic respiratory failure [38], treatment with non-invasive oxygenation strategies compared with standard oxygen therapy was associated with lower risk of death. Most of the included studies predated the RECOVERY trial [39] and there was no consistent reporting on use of steroids or other disease modifying therapies limiting interpretation of the findings of the review.

Although there were no reported major adverse events following PP not all included studies reported adverse events. Therefore, safety and efficacy of this intervention can only be tested in a well-designed randomised controlled trial and they are ongoing [40, 41]. Placing critically ill, hypoxaemic, non-intubated patients in a prone position outside closely monitored units without ability to administer invasive mechanical ventilation when required may lead to poor outcomes. PP should be carefully undertaken in systems where this can be safely provided pending further evidence. Equally, PP may be considered as a useful adjunct in patients who are considered not suitable candidates for invasive mechanical ventilation while making sure their comfort and dignity is also prioritised.

In a selected group of patients who received PP, the incidence of intubation and mortality was relatively lower in comparison with a recent systematic review and meta-analysis on associations of non-invasive oxygenation strategies and all-cause mortality in COVID-19, which reported rates of 40% and 30% respectively [38]. In the absence of appropriate controls who did not receive PP for comparison, it is unclear whether these physiologic improvements resulted in reduced need for intubation or mortality. A noticeable difference was observed between the patients who had PP in ICU compared with other areas of the hospital both in terms of improvement in oxygenation and intubation rates. The oxygenation improvements were more marked in patients who underwent PP in ICU and there were corresponding lower intubation rates in ICU patients. However, a recent cohort study did not show any reduction in intubation rates or 28-day mortality in COVID-19 patients who received awake PP as an adjunctive therapy to HFNO [42]. It is possible that a selected patient population of non-intubated patients with COVID-19-related respiratory failure may benefit from PP. However, data available for this review was not of sufficient quality to identify the precise population that may benefit. Based on this review, PP appears feasible and safe in patients who are hypoxaemic and when undertaken in appropriately monitored environments.

Our study has some important limitations. This review was based on data from single arm observational case series and cohort studies that had no comparator groups. Consequently, heterogeneity and all the antecedent biases associated with patient selection and reporting was expected. The heterogeneity persisted despite sensitivity analyses were performed based on sample size. Given the inconsistent reporting of oxygenation parameters, we had to derive some of the variables from other reported variables and where possible requested missing data from the corresponding authors of the included studies. Despite this, we still had missing variables in some of the included studies. This calls for a validated system to report changes in physiologic parameters in future studies that test respiratory supports in non-intubated patients. Healthcare worker infection risks and rates while assisting/facilitating PP were not reported in any of the studies. In addition, strong conclusions cannot be reached due to several factors: first, the absence of tested, established triggers and a standardised process for initiating PP in non-intubated COVID-19 patients; second, the significant heterogeneity in the patient populations included and lack of granular data on co-interventions used (NIV, HFNC, steroids, antiviral therapies etc.); third, an absence of standardised intubation criteria; and, fourth, that the intervention was provided in some instances under pandemic stressors that affected resource availability.

Conclusion
There was a variable but significant improvement in oxygenation parameters with PP in non-intubated, hypoxic adult patients with COVID-19-related hypoxaemia. This review observed a lack of a standardised process for PP in non-intubated patients. Significant heterogeneity, inconsistent reporting, poor data quality and potential biases in data may affect the analysis. Absence of standardised intubation criteria and the provision of the intervention under pandemic stressors further limit interpretation. Well designed, randomised control studies testing the efficacy of PP in non-intubated COVID-19 patients are needed prior to widespread adoption of this practice.

Declarations

ACKNOWLEDGMENT:
We thank authors of all the studies for providing us with the data needed for our systematic review and meta-analysis. We are also grateful to Dr. Ata Mahmoodpoor, Dr. Xu Q, Dr. Tom Lawton, Dr. Caputo for responding to our request for additional information used in this study. Prof Shekar acknowledges
No ethics approval was needed as the data was extracted from published research papers. The published papers had ethics approval and patients consent.

Ethics approval and Consent of participants:

We hope to disseminate this important information through your esteemed open-access journal, due to its wide global reach and impact on medical professionals all over the world. All authors are happy for the manuscript to be submitted to “Critical Care” journal. This manuscript has not been published in any journal.

Availability of data and material:

All the data analysed in this study is included in the main article and additional files. Extra information that was obtained from some of the studies after contacting the authors is available from the corresponding author on reasonable request.

Authors’ contributions:

KS and AS conceived the study idea and co-ordinated the review process. MR, AS, ZL, AZ and KS drafted the review protocol, conducted the systematic review, assisted with data analysis and wrote the initial draft of the manuscript. MR and AS contributed equally. SW assisted with literature search. AZ designed the summary tables. AA and BB conducted the statistical analysis and wrote sections of the manuscript. EF made significant contributions to the analysis plan. GB, RT, KR, DB and EF critically evaluated the manuscript and contributed to writing of the manuscript. All authors critically reviewed the manuscript and approved the final version prior to submission.

Consent for publication:

No ethics approval was needed as the data was extracted from published research papers. The published papers had ethics approval and patients consent and as our systematic review. No extra information about patients in this systematic review and meta-analysis.

References


19. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp]


Figures
Figure 1: PRISMA flowchart of study inclusions and exclusions.

PRISMA (Preferred reporting items for systematic reviews and meta-analyses) flowchart of study inclusions and exclusions.

Figure 1

PRISMA (Preferred reporting items for systematic reviews and meta-analyses) flowchart of study inclusions and exclusions.
Figure 2: Graphical representation of mean improvements in physiological parameters post-PP

Graphical representation of mean improvements in physiological parameters post-PP
Figure 3: Primary Outcome demonstrating the physiological parameters post-PP

### PaO2/FiO2

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-PP Mean N</th>
<th>Pre-PP Mean SD</th>
<th>Mean Difference with 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cookson et al. April 2020</td>
<td>10 81</td>
<td>8.63</td>
<td>55.71</td>
<td>1.11</td>
</tr>
<tr>
<td>Donnai et al. June 2020</td>
<td>10 203</td>
<td>5.06</td>
<td>146.98</td>
<td>2.07</td>
</tr>
<tr>
<td>Drummond et al. May 2020</td>
<td>6 1063</td>
<td>45.45</td>
<td>163.02</td>
<td>6.97</td>
</tr>
<tr>
<td>Ding et al. Sept 2020</td>
<td>10 132</td>
<td>37.88</td>
<td>136.59</td>
<td>52.59</td>
</tr>
<tr>
<td>Driscoll et al. May 2020</td>
<td>10 314</td>
<td>3.77</td>
<td>105.29</td>
<td>8.25</td>
</tr>
<tr>
<td>Dowden et al. June 2020</td>
<td>10 517</td>
<td>47.97</td>
<td>186.90</td>
<td>6.41</td>
</tr>
<tr>
<td>Ellis et al. May 2020</td>
<td>10 114</td>
<td>3.87</td>
<td>105.29</td>
<td>8.25</td>
</tr>
<tr>
<td>Fastow et al. May 2020</td>
<td>10 132</td>
<td>37.88</td>
<td>136.59</td>
<td>52.59</td>
</tr>
<tr>
<td>Foy et al. May 2020</td>
<td>10 176</td>
<td>27.94</td>
<td>152.09</td>
<td>42.59</td>
</tr>
<tr>
<td>Gao et al. May 2020</td>
<td>20 520</td>
<td>5.61</td>
<td>84.84</td>
<td>3.52</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Heterogeneity:** I² = 99.7%, T² = 1.828, p < 0.0001
Test of H0: Q(12) = 3044.84, p < 0.0001

### PaO2

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-PP Mean N</th>
<th>Pre-PP Mean SD</th>
<th>Mean Difference with 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copas et al. April 2020</td>
<td>5 69</td>
<td>4.40</td>
<td>46.53</td>
<td>11.14</td>
</tr>
<tr>
<td>Copas et al. June 2020</td>
<td>4 263</td>
<td>9.54</td>
<td>117.10</td>
<td>6.65</td>
</tr>
<tr>
<td>Donnai et al. July 2020</td>
<td>10 132</td>
<td>37.88</td>
<td>136.59</td>
<td>52.59</td>
</tr>
<tr>
<td>Ellis et al. May 2020</td>
<td>10 200</td>
<td>137.88</td>
<td>46.53</td>
<td>11.14</td>
</tr>
<tr>
<td>Foy et al. May 2020</td>
<td>10 176</td>
<td>27.94</td>
<td>152.09</td>
<td>42.59</td>
</tr>
<tr>
<td>Gao et al. May 2020</td>
<td>20 520</td>
<td>5.61</td>
<td>84.84</td>
<td>3.52</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Heterogeneity:** I² = 99.7%, T² = 1.828, p < 0.0001
Test of H0: Q(12) = 3044.84, p < 0.0001

### SpO2

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-PP Mean N</th>
<th>Pre-PP Mean SD</th>
<th>Mean Difference with 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copas et al. April 2020</td>
<td>5 69</td>
<td>4.40</td>
<td>46.53</td>
<td>11.14</td>
</tr>
<tr>
<td>Donnai et al. June 2020</td>
<td>10 132</td>
<td>37.88</td>
<td>136.59</td>
<td>52.59</td>
</tr>
<tr>
<td>Ellis et al. May 2020</td>
<td>10 200</td>
<td>137.88</td>
<td>46.53</td>
<td>11.14</td>
</tr>
<tr>
<td>Fastow et al. May 2020</td>
<td>10 176</td>
<td>27.94</td>
<td>152.09</td>
<td>42.59</td>
</tr>
<tr>
<td>Foy et al. May 2020</td>
<td>10 176</td>
<td>27.94</td>
<td>152.09</td>
<td>42.59</td>
</tr>
<tr>
<td>Gao et al. May 2020</td>
<td>20 520</td>
<td>5.61</td>
<td>84.84</td>
<td>3.52</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Heterogeneity:** I² = 99.7%, T² = 1.828, p < 0.0001
Test of H0: Q(12) = 3044.84, p < 0.0001

Random effects REMM model,

**PaO2**

**PaO2**

**SpO2**

Random effects REMM model,

Figure 3

Primary Outcome demonstrating the physiological parameters post-PP.
Figure 4: Secondary Outcomes: Forest plots for rates of intubation and mortality in patients who underwent PP.

**Intubation**

<table>
<thead>
<tr>
<th>Study</th>
<th>Total intubated</th>
<th>Intubated with 95% CI</th>
<th>Weight (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caputo et al., April 2020</td>
<td>50</td>
<td>0.40 [0.27, 0.50]</td>
<td>0.40</td>
</tr>
<tr>
<td>Capua et al., June 2020</td>
<td>46</td>
<td>0.28 [0.19, 0.41]</td>
<td>0.52</td>
</tr>
<tr>
<td>Clemente et al., June 2020</td>
<td>10</td>
<td>0.20 [0.04, 0.44]</td>
<td>0.50</td>
</tr>
<tr>
<td>Despres et al., May 2020</td>
<td>6</td>
<td>0.30 [0.16, 0.61]</td>
<td>4.12</td>
</tr>
<tr>
<td>Dong et al., May 2020</td>
<td>15</td>
<td>0.00 [-0.13, 0.13]</td>
<td>0.43</td>
</tr>
<tr>
<td>Ethor en et al., May 2020</td>
<td>24</td>
<td>0.21 [0.08, 0.33]</td>
<td>7.57</td>
</tr>
<tr>
<td>Golestan-Ghafte et al., May 2020</td>
<td>10</td>
<td>0.20 [0.04, 0.44]</td>
<td>0.50</td>
</tr>
<tr>
<td>Lawton et al., June 2020</td>
<td>105</td>
<td>0.14 [0.09, 0.19]</td>
<td>10.31</td>
</tr>
<tr>
<td>Mehdizadeh et al., June 2020</td>
<td>10</td>
<td>0.30 [0.16, 0.61]</td>
<td>2.79</td>
</tr>
<tr>
<td>Rekvi et al., July 2020</td>
<td>26</td>
<td>0.27 [0.10, 0.43]</td>
<td>7.46</td>
</tr>
<tr>
<td>Senin et al., May 2020</td>
<td>15</td>
<td>0.07 [0.03, 0.22]</td>
<td>7.49</td>
</tr>
<tr>
<td>Thompson et al., June 2020</td>
<td>29</td>
<td>0.41 [0.34, 0.48]</td>
<td>7.34</td>
</tr>
<tr>
<td>Tu et al., May 2020</td>
<td>5</td>
<td>0.22 [0.03, 0.41]</td>
<td>5.26</td>
</tr>
<tr>
<td>Xu et al., May 2020</td>
<td>10</td>
<td>0.30 [0.16, 0.44]</td>
<td>6.07</td>
</tr>
</tbody>
</table>
**Overall**               |                 | 0.20 [0.12, 0.28]     |            |

Heterogeneity: $I^2 = 71.30$, $Q = 74.28$, $p = 3.88$

Total of $I^2$: 39 (15) = 4.80, $p = 0.03$

Test of $I^2$: 43.68, $p = 0.00$

Random-effects REML model

**Mortality**

<table>
<thead>
<tr>
<th>Study</th>
<th>Total Death</th>
<th>Mortality rate with 95% CI</th>
<th>Weight (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caputo et al., June 2020</td>
<td>40</td>
<td>0.11 [0.03, 0.29]</td>
<td>4.60</td>
</tr>
<tr>
<td>Despres et al., May 2020</td>
<td>6</td>
<td>0.63 [0.46, 0.61]</td>
<td>7.15</td>
</tr>
<tr>
<td>Dong et al., May 2020</td>
<td>15</td>
<td>0.63 [0.43, 0.83]</td>
<td>1.26</td>
</tr>
<tr>
<td>Ethor en et al., May 2020</td>
<td>24</td>
<td>0.63 [0.40, 0.86]</td>
<td>8.50</td>
</tr>
<tr>
<td>Golestan-Ghafte et al., May 2020</td>
<td>10</td>
<td>0.63 [0.40, 0.86]</td>
<td>8.50</td>
</tr>
<tr>
<td>Lawton et al., June 2020</td>
<td>105</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
<tr>
<td>Mehdizadeh et al., June 2020</td>
<td>10</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
<tr>
<td>Rekvi et al., July 2020</td>
<td>26</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
<tr>
<td>Senin et al., May 2020</td>
<td>15</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
<tr>
<td>Thompson et al., June 2020</td>
<td>29</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
<tr>
<td>Tu et al., May 2020</td>
<td>5</td>
<td>0.04 [0.04, 0.44]</td>
<td>5.26</td>
</tr>
<tr>
<td>Xu et al., May 2020</td>
<td>10</td>
<td>0.04 [0.04, 0.44]</td>
<td>6.07</td>
</tr>
</tbody>
</table>
**Overall**               |             | 0.04 [0.04, 0.44]         |            |

Heterogeneity: $I^2 = 92.91$, $Q = 33.25$, $p = 6.30$

Total of $I^2$: 39 (15) = 4.80, $p = 0.03$

Test of $I^2$: 43.68, $p = 0.00$

Random-effects REML model

Figure 4

Secondary outcomes: Forest plots for rates of intubation and mortality in patients who underwent PP.
Secondary Analysis based on P/F ratio demonstrate that PaO2/FiO2 ≤150 pre-PP had statistically significant improvements when compared with PaO2/FiO2 >150.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AdditionalFigure1.jpeg
- AdditionalFigure2.jpeg
- AdditionalFigure3.jpeg
- AdditionalFigure4.jpeg
- AdditionalFigure5.jpeg
- AdditionalFigure6.jpeg
- AdditionalFigure7.jpeg
- AdditionalTable1.pdf
- AdditionalTable2.pdf
- AdditionalTable3.pdf
- AdditionalTable4.pdf
- AdditionalTable5.pdf